Table of Contents Author Guidelines Submit a Manuscript
Journal of Parasitology Research
Volume 2017, Article ID 1964531, 11 pages
Research Article

Construction of Two mCherry Plasmids (pXG-mCherry) for Transgenic Leishmania: Valuable Tools for Future Molecular Analysis

1Instituto de Salud Tropical (ISTUN), University of Navarra, Pamplona, Spain
2IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
3Department of Microbiology and Parasitology, University of Navarra, Pamplona, Spain

Correspondence should be addressed to Paul A. Nguewa; se.vanu@aweugnap

Received 24 September 2016; Revised 12 December 2016; Accepted 27 December 2016; Published 13 February 2017

Academic Editor: José F. Silveira

Copyright © 2017 Andrés Vacas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Leishmania is the causative agent of leishmaniasis, a neglected tropical disease that affects more than 12 million people around the world. Current treatments are toxic and poorly effective due to the acquisition of resistance within Leishmania populations. Thus, the pursuit for new antileishmanial drugs is a priority. The available methods for drug screening based on colorimetric assays using vital dyes are time-consuming. Currently, the use of fluorescent reporter proteins is replacing the use of viability indicator dyes. We have constructed two plasmids expressing the red fluorescent protein mCherry with multiple cloning sites (MCS), adequate for N- and C-terminal fusion protein constructs. Our results also show that the improved pXG-mCherry plasmid can be employed for drug screening in vitro. The use of the red fluorescent protein, mCherry, is an easier tool for numerous assays, not only to test pharmacological compounds, but also to determine the subcellular localization of proteins.